Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

Imovax Polio is used for active immunization against poliovirus infection, a viral disease that can cause paralytic poliomyelitis.

• Poliomyelitis (polio): provides protective immunity that prevents infection with poliovirus types 1, 2 and 3.
• Routine childhood immunization: incorporated into standard immunization schedules to protect infants and young children.
• Travel to endemic regions: ensures travelers are immunized against poliovirus before exposure.
• Outbreak control: employed in mass vaccination campaigns to halt poliovirus transmission in affected communities.
• Post‑exposure prophylaxis (when indicated): may be administered to individuals with recent exposure to poliovirus to boost immunity.

• Imovax Polio contains inactivated whole poliovirus particles of types 1, 2 and 3. After intramuscular or subcutaneous injection, the viral antigens are taken up by antigen‑presenting cells, processed and displayed to T‑cells, which stimulate B‑cell differentiation and production of neutralising antibodies. The resulting humoral response blocks viral attachment and replication, conferring active immunity without risk of disease from the vaccine strain.

Common Side Effects

• Pain at the injection site: mild to moderate discomfort where the vaccine is administered.
• Redness or swelling: localized inflammatory reaction that typically resolves within a few days.
• Fever: low‑grade temperature elevation occurring within 24‑48 hours.
• Headache: transient headache reported by some recipients.
• Fatigue: temporary feeling of tiredness after vaccination.
• Muscle aches: mild soreness in nearby muscles.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare autoimmune neuropathy that may develop weeks after vaccination.
• Seizures: infrequent occurrence, particularly in children with pre‑existing neurological conditions.
• Severe rash or urticaria: extensive skin reactions indicating hypersensitivity.
• Hypotension: sudden drop in blood pressure following injection.
• Encephalitis: extremely rare inflammation of the brain.

Before administering Imovax Polio, consider the following precautions:

• Screen for severe allergy: avoid in individuals with known hypersensitivity to any vaccine component.
• Delay vaccination: postpone in persons with acute moderate or severe illness.
• Pregnancy: use only if the potential benefit justifies the potential risk; data are limited.
• Immunocompromised patients: vaccine is inactivated and generally safe, but monitor immune response.
• Concurrent vaccines: may be given with other injectable vaccines at separate sites.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other agents as follows:

Major Interactions (Avoid)

• Live viral vaccines: avoid simultaneous administration due to potential interference with immune response.
• Immunoglobulin therapy: may reduce vaccine efficacy if given within 2 weeks of vaccination.

Moderate Interactions (Monitor Closely)

• Antipyretics: may mask fever but do not affect immunogenicity.
• High‑dose corticosteroids: may blunt antibody response; monitor serologic titers.
• Blood products: may interfere with serologic testing for vaccine‑induced antibodies.